Tom Bainbridge

Corrs Chambers Westgarth (Sydney)
Special Counsel

Tom Bainbridge advises on antitrust and competition law, representing global corporations across all sectors on matters concerning merger control, cartels and misuse of market power. He has particular expertise in financial services and payments, having represented investment banks in a series of cartel investigations that followed the global financial crisis, and advising them subsequently on regulatory developments and compliance risks. His expertise further extends to digital markets, having represented a number of technology firms in the recent wave of abuse of dominance investigations, market investigations and regulatory reform in the EU, the UK and Australia. He also represents clients in major M&A deals, advising them on merger control matters, and representing them before competition authorities. Prior to joining Corrs, Tom was Special Counsel at a leading US law firm in London and Brussels.


Auteurs associés

Corrs Chambers Westgarth (Sydney)
Corrs Chambers Westgarth
Corrs Chambers Westgarth (Melbourne)


5681 Bulletin

Frances M. Murphy, Matt Evans, Stephen Brown, Tom Bainbridge The England & Wales Court of Appeal holds that the UK Competition Appeal Tribunal has no discretion to extend limitations period for follow-on actions against alleged cartelists (BCL, BASF)


On 12 November 2010, the Court of Appeal for England and Wales ruled that the UK Competition Appeal Tribunal (CAT) does not have discretion to extend the time period within which follow-on actions for damages may be commenced. The Court of Appeal’s judgment provides important clarification of (...)

Frances M. Murphy, Tom Bainbridge The EU Court of Justice reverses the Commission decision regarding the legality of dual pricing arrangments between leading pharmaceutical undertaking and Spanish wholesalers (GlaxoSmithKline)


On 6 October 2009, the European Court of Justice (ECJ) issued its judgment in the long-running wrangle regarding the legality of GlaxoSmithKline’s (GSK) dual pricing arrangements with Spanish pharmaceutical wholesalers. As a result of the judgment, the European Commission (Commission) will (...)


Total des visites

Nombre de lectures par contribution

Nombre de contributions

Classement de l'auteur
En nombre de contributions
En nombre total de visites
En nombre moyen de visites
Envoyer un message